AtriCure

ATRC

Market cap $1.49B

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, May 5, 2026, to discuss its first quarter financial results. Those interested in listening to th.

ArtiCure Chief Science Officer sold 5,000 shares for a transaction value of approximately $149,000 at around $29.83 per share on March 12, 2026. The sale represented 4.91% of Vinayak's direct holdings, reducing direct ownership from 101,875 to 96,875 shares.

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Citizens Life Sciences Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday, March 10, 2026, at 1:05 p.m. Eastern Time. Interested parties may access a live audio.

The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

AtriCure, Inc. (ATRC) Q4 2025 Earnings Call Transcript

AtriCure (ATRC) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.08 per share a year ago.

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2025 and full year 2025 financial results. “Our 2025 performance reflects strong execution and continued momentum in our business. We delivered 15% revenue growth for the year and strengthened profitability while advancing key innovation and c.

AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, February 17, 2026, to discuss its fourth quarter and full year 2025 financi.

AtriCure tops a screen of high-efficiency stocks, joined by REV Group, Oceaneering International and Analog Devices after beating industry averages.